# Patrick A. Ott

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/patrick-a-ott/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,764 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 82 |
| i10-index | 208 |
| Last Known Institution | Broad Institute |
| OpenAlex ID | https://openalex.org/A5041066193 |
| ORCID iD | https://orcid.org/0000-0002-4253-943X |
| Works | 618 |

## Researcher papers

- [A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade](https://scholariq.org/papers/a-cancer-cell-program-promotes-t-cell-exclusion-and-resistance-to-checkpoint/)
- [Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors](https://scholariq.org/papers/clinicopathological-features-of-acute-kidney-injury-associated-with-immune/)
- [<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids](https://scholariq.org/papers/i-ex-vivo-i-profiling-of-pd-1-blockade-using-organotypic-tumor-spheroids/)
- [PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course](https://scholariq.org/papers/pd-1-inhibitor-related-pneumonitis-in-advanced-cancer-patients-radiographic/)
- [Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor](https://scholariq.org/papers/phase-ii-study-of-the-mek1-mek2-inhibitor-trametinib-in-patients-with-metastatic/)
- [Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort](https://scholariq.org/papers/nivolumab-monotherapy-and-nivolumab-plus-ipilimumab-in-recurrent-small-cell-lung/)
- [A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant](https://scholariq.org/papers/a-multi-center-study-on-safety-and-efficacy-of-immune-checkpoint-inhibitors-in/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Researcher university

- [Broad Institute](https://scholariq.org/institutions/broad-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.